INS and diabetes mellitus: Additionally, they estimated that 90% (IQR = 80% − 91%) of their patients with diabetes required insulin therapy, 45% (IQR = 30% − 80%) of their patients with diabetes had T1D, 80% (IQR = 58% − 86%) of their patients who qualified for CGM devices based upon the American Diabetes Association (ADA)'s 2024 Standards of Care criteria regularly used them, and 50% (IQR = 48% − 63%) of their patients who qualified for insulin pumps based upon the ADA's 2024 Standards of Care criteria regularly used them [23].